Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Down – Should You Sell?

Fresenius SE & Co. (OTCMKTS:FSNUY) shares gapped down before the market opened on Thursday. The stock had previously closed at $12.19, but opened at $11.63. Fresenius SE & Co. shares last traded at $11.6825, with a volume of 18,360 shares trading hands.

Analyst Ratings Changes

FSNUY has been the subject of several recent research reports. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy”.

Fresenius SE & Co. Price Performance

The stock has a 50 day moving average of $13.16 and a two-hundred day moving average of $12.37. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.28. The firm has a market capitalization of $26.27 billion, a P/E ratio of 14.76 and a beta of 0.60.

Fresenius SE & Co. (OTCMKTS:FSNUY) last announced its earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%.The company had revenue of $6.91 billion for the quarter, compared to the consensus estimate of $6.65 billion. Sell-side analysts predict that Fresenius SE & Co. will post 1.08 earnings per share for the current fiscal year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.